Post-earnings recap
Reported
Mon, May 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that CRISPR Therapeutics is facing challenges, particularly reflected in the larger-than-expected loss per share. The stock dropped nearly 10% in reaction, signaling investor concern over the company's current performance and lack of guidance. Without clear direction from management, investors may remain cautious in the near term.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.32 | N/A | -21.40% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about current operational hurdles. They did not provide any updates on future guidance, indicating uncertainty.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting operational goals.